Surgical Versus Medical Treatment of Acromegaly
Completed
- Conditions
- Acromegaly
- Registration Number
- NCT01000090
- Lead Sponsor
- University of Aarhus
- Brief Summary
Evaluate biochemical differences in acromegalic patients treated with surgery versus somatostatin analogues (SMS) (after surgery or alone).
Hypothesis: Treatment modality exhibit different biochemical responses in acromegaly.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 63
Inclusion Criteria
- Acromegaly diagnosis
- treated with Somatostatin analogues or surgery
- in treatment control
Exclusion Criteria
- treatment with GH-antagonist
- never treated
- not in treatment control
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie differential IGF-1 regulation in surgical vs medical acromegaly treatment?
How does transsphenoidal surgery compare to somatostatin analogs in normalizing GH/IGF-1 levels long-term?
Which biomarkers predict response to somatostatin analogs versus surgical resection in acromegaly patients?
What are the adverse event profiles of somatostatin analog therapy versus pituitary surgery for acromegaly?
How do dopamine agonists and GH receptor antagonists compare to somatostatin analogs in acromegaly management?
Trial Locations
- Locations (1)
Århus University Hospital, Medical department M
🇩🇰Århus, Denmark
Århus University Hospital, Medical department M🇩🇰Århus, Denmark